dIvergEnt : How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies
Palomares, Óscar (Universidad Complutense de Madrid)
Sánchez-Ramón, Silvia (Universidad Complutense de Madrid. Departamento de Microbiología y Parasitología)
Dávila, Ignacio (Instituto de Investigación Biomédica de Salamanca)
Prieto, Luis (Hospital Universitari Doctor Peset (València))
Pérez de Llano, Luis (Hospital Universitario Lucus Augusti (Lugo))
Lleonart, Marta (Novartis Farmacéutica (Espanya))
Domingo, Christian (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Nieto García, Antonio (Hospital Universitari i Politècnic La Fe (València))
Universitat Autònoma de Barcelona

Date:	2017
Abstract:	Asthma is an airway disease characterised by chronic inflammation with intermittent or permanent symptoms including wheezing, shortness of breath, chest tightness, and cough, which vary in terms of their occurrence, frequency, and intensity. The most common associated feature in the airways of patients with asthma is airway inflammation. In recent decades, efforts have been made to characterise the heterogeneous clinical nature of asthma. The interest in improving the definitions of asthma phenotypes and endotypes is growing, although these classifications do not always correlate with prognosis nor are always appropriate therapeutic approaches. Attempts have been made to identify the most relevant molecular and cellular biomarkers underlying the immunopathophysiological mechanisms of the disease. For almost 50 years, immunoglobulin E (IgE) has been identified as a central factor in allergic asthma, due to its allergen-specific nature. Many of the mechanisms of the inflammatory cascade underlying allergic asthma have already been elucidated, and IgE has been shown to play a fundamental role in the triggering, development, and chronicity of the inflammatory responses within the disease. Blocking IgE with monoclonal antibodies such as omalizumab have demonstrated their efficacy, effectiveness, and safety in treating allergic asthma. A better understanding of the multiple contributions of IgE to the inflammatory continuum of asthma could contribute to the development of novel therapeutic strategies for the disease.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Allergy ; Asthma ; Immunoglobulin E (IgE) ; Biomarkers ; Immunological mechanisms ; Immunomodulation ; Biological treatment ; Anti-ige ; Omalizumab
Published in:	International journal of molecular sciences, Vol. 18 (june 2017) , ISSN 1422-0067

DOI: 10.3390/ijms18061328
PMID: 28635659

14 p, 3.8 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles